Market Cap | 22.23M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -2.89M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 7.00% |
Sales | 19.5k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 2.00% |
Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -50.00% |
Recommedations | - | Quick Ratio | 6.53 | Shares Outstanding | 389.89M | 52W Low Chg | 50.00% |
Insider Own | 5.00% | ROA | -104.13% | Shares Float | 370.51M | Beta | 1.49 |
Inst Own | - | ROE | -191.32% | Shares Shorted/Prior | -/- | Price | 0.06 |
Gross Margin | -30.95% | Profit Margin | - | Avg. Volume | 403,981 | Target Price | - |
Oper. Margin | -14,323.83% | Earnings Date | May 2 | Volume | 382,522 | Change | -4.76% |
Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Korenko Michael K | CEO AND PRESIDENT CEO AND PRESIDENT | Oct 18 | Buy | 0.0536 | 100,000 | 5,360 | 9,985,090 | 10/19/23 |
POLLACK MICHAEL H | INTERIM CFO INTERIM CFO | Mar 24 | Sell | 0.0624 | 16,000 | 998 | 03/27/23 | |
Korenko Michael K | CEO AND PRESIDENT CEO AND PRESIDENT | Dec 15 | Buy | 0.0466 | 100,000 | 4,660 | 9,885,090 | 12/15/22 |
Korenko Michael K | CEO AND PRESIDENT CEO AND PRESIDENT | Nov 17 | Buy | 0.0517 | 200,000 | 10,340 | 9,785,090 | 11/18/22 |
Korenko Michael K | CEO AND PRESIDENT CEO AND PRESIDENT | Mar 27 | Buy | 0.06 | 100,000 | 6,000 | 9,584,890 | 03/29/22 |